COVID-19 and Parkinson’s Disease: Are We Dealing with Short-term Impacts or Something Worse?

Daniella Balduino Victorino, Marcia Guimarães-Marques, Mariana Nejm, Fulvio Alexandre Scorza and Carla Alessandra Scorza

Department of Neurology and Neurosurgery, Discipline of Neuroscience, Federal University of São Paulo/Paulista Medical School, São Paulo, SP, Brazil

We read with great interest the commentary by Helmich and Bloem [1] in which the authors suggested that patients with Parkinson’s disease (PD) may not only face a greater risk of developing worse coronavirus disease 2019 (COVID-19)-related respiratory outcomes, but also a variety of “hidden sorrows” of the pandemic. The authors argue that PD patients may suffer from chronic stress and lack of physical activity associated with social isolation. As the COVID-19 continues snaking its way around the world (as of April 29, 2020, global cases topped 3 million), we would like to further highlight several impacts that the ongoing COVID-19 pandemic may induce on the global burden of PD.

Preliminary studies suggested that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is the etiologic agent of the COVID-19, may have a potential neurotropism in humans though such feature has not been conclusively demonstrated yet [2, 3]. Similar to other respiratory viruses, the SARS-CoV-2 may gain access to the Central Nervous System (CNS) by the hematogenous route or axonal transport along with the olfactory neuroepithelium [4, 5]. The olfactory pathway hypothesis for SARS-CoV-2 neuroinvasion is supported by the fact that several patients with COVID-19 infection have experienced hyposmia/anosmia and dysgeusia [6–9]. Indeed, the interesting aspect of such a route (from the nasal cavity to the olfactory bulb, then to the piriform cortex, and finally to the brainstem) is the potential presence of the virus in the brainstem, which contains the respiratory nuclei responsible for breathing rhythm [5, 10]. In fact, more than half of the patients with COVID-19 infection showed respiratory distress [3, 11, 12].

In the clinical scenario, nearly 50% of all emerging viruses present neurological symptoms in the acute phase [13]. Such feature does not seem to be different for COVID-19, since several patients reportedly showed neurologic manifestations [3, 11, 14]. For example, patients with the severe form of the COVID-19 infection were more likely to develop acute cerebrovascular disease, consciousness disturbance, and skeletal muscle injury [6]. In addition, an evidence of encephalopathy and intracerebral haemorrhage was found on brain imaging scans of patients with the SARS-CoV-2 infection [15–17]. Finally, a case of COVID-19-related meningitis/encephalitis and a case of COVID-19 infection associated with Guillain-Barré syndrome have recently been reported [15, 18]. It would be of interest to further investigate cerebrospinal fluid (CSF) samples as well as post-mortem brain and spinal cord tissue from deceased COVID-19 patients (whenever possible) to probe for any direct evidence of CNS infection [19].

*Correspondence to: Carla Alessandra Scorza, Department of Neurology and Neurosurgery, Escola Paulista de Medicina/Universidade Federal de São Paulo – EPM/UNIFESP, Av. Pedro de Toledo, 699, 1º andar, São Paulo-SP, Brazil. E-mail: carla.scorza@unifesp.br.
On the other hand, the burden of the long-term neurological morbidity from neuroinfectious diseases is largely unknown [13]. A growing body of evidence suggests that the pathological process of PD may be modulated (or initiated) by viruses or other pathogens [20–25]. An early evidence of a potential link between viruses and PD stems from an epidemic of Encephalitis Lethargica (EL), following the 1918 influenza outbreak. In that occasion, nearly all patients who had an acute episode of EL developed post-encephalitic Parkinsonism, a condition that closely resembled the clinical picture of PD [26]. Although the evidence linking EL to PD pathogenesis was correlational, it readily prompted the scientific community to further investigation. For example, Jang et al. showed that the administration of nonlethal doses of the highly pathogenic H5N1 influenza virus into mice noses induced microglia activation as well as α-synuclein phosphorylation and aggregation in brain areas infected by the virus, which persisted long after the infection was resolved [22]. The study also showed a significant long-lasting loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) [22]. A later study that examined the neurotropic and inflammatory potential of the A/California/04/2009 (CA/09) H1N1 virus showed that, although no evidence of a viral neurotropism was found, CA/09 H1N1 virus robustly increased microglial activity in the SNpc of the mice [23]. In addition, an altered expression of several neurotrophic factors and cytokine-related genes was detected, following the CA/09 H1N1 infection [23]. Finally, the hypothesis that viral infections may contribute to PD pathogenesis is not limited to the influenza virus, since some of the cardinal motor symptoms and histological features of PD have been also associated with other viruses (e.g., coxsackie virus, West Nile virus, Japanese encephalitis B virus, Saint Louis encephalitis virus, and HIV) [20, 27].

We acknowledge that further research is needed to better elucidate the role of viruses in the pathogenesis of PD. Nevertheless, the above findings have significant clinical implications as they suggest a potential contribution of both neurotropic and non-neurotropic viruses to the initiation of PD neurodegeneration, either directly (by the physical presence of the virus in the CNS parenchyma) or indirectly (by inducing a long-lasting inflammatory process in the brain). However, triggers per se may be, in most cases, insufficient for PD to develop [28]. Thus, ‘facilitators’ have been suggested to play a role in PD pathogenesis, either by acting concomitantly with the triggering event (e.g., a viral infection) or after it. Such processes usually take place in the prodromal or asymptomatic phase of PD [28]. Among the several ‘facilitators’ that may affect the progression of PD, the aging and cellular senescence have by far the most recognized impact. For example, the global prevalence of PD was 2–3% of the population aged >65 years in 2017, and such number is set to reach over 14 million cases worldwide by 2040, which makes PD the fastest growing disorder among all neurological disorders [29]. Such exponential growth is sustained by the continuously aging of the population [30]. Independently of PD, global life expectancy has increased by approximately six years in the past couple of years [31]. As longevity increases, so does the number of persons living with PD, which may lead to greater financial and social burdens [29]. In fact, estimates suggest that a PD pandemic is on the rise [29, 32].

Although it is too early to suggest what long-term neurological outcomes the survivors of COVID-19 infection may face, some evidence may come from previous pandemics of respiratory viruses. First, given that SARS-CoV-2 may induce a cytokine storm syndrome and hyperinflammation in patients with severe COVID-19 infection [33], is it possible to hypothesize that SARS-CoV-2/COVID-19 infection could be a triggering event of the neurodegenerative cascade underlying PD [19]? In addition, previous studies showed that other human coronaviruses may remain latent in leukocytes and thus may be prone to producing latent or persistent infections of the CNS [34]. While clinical signs of Parkinsonism and PD have not been associated with previous outbreaks of coronaviruses, anti-coronavirus antibodies were detected in the CSF samples of persons with PD [35]. Second, could COVID-19 survivors represent a disproportionately large fraction of the future PD patient population? Although the extant evidence is still inconclusive, previous studies reported that persons who were born or were young at the time of the 1918 influenza outbreak had a 2- to 3-fold higher risk of developing PD than those born prior to 1888 or after 1924 [36, 37]. Finally, could the future burden of PD be affected by the COVID-19 pandemic?

The scientific community can also offer a glimmer of hope amid COVID-19 pandemic. Sadasivan and colleagues previously showed that prophylactic treatment with either vaccine or antiviral therapy was effective in protecting mice against the synergistic effects of H1N1 influenza virus and MPTP (a neurotoxin used to model PD in animals) on SNpc dopaminergic neuronal loss [24]. Driven by the
COVID-19 pandemic’s spread, a worldwide effort is now underway to find vaccines and viable therapies against SARS-CoV-2.

In conclusion, COVID-19 pandemic has disrupted modern society on an unprecedented scale. The long-term link between viruses and neurodegenerative disorders is difficult to demonstrate, but we should not cast aside the long-lasting impacts that the growing COVID-19 pandemic may have on the pandemic of PD. In fact, such concern has been widely shared by the scientific community [38-40]. It would be of interest to adopt strategies to closely follow up COVID-19 survivors. For example, health systems should keep accurate medical records (clinical and imaging biomarkers) to aid specialists and researchers to address the long-term deleterious effects of SARS-CoV-2 on CNS (and their potential association with neurodegenerative disorders such as PD) in the coming years [19, 39, 40]. As other global pandemics in the past, the COVID-19 pandemic will likely last for a limited length of time. Yet, it is about time we recognize that the pandemic of PD is not going away anytime soon.

ACKNOWLEDGMENTS

DBV is currently funded by postgraduate fellowship from São Paulo Research Foundation (FAPESP #2016/17746-3). FAS is currently funded by São Paulo Research Foundation (FAPESP #2018/18568-7). The National Council for Scientific and Technological Development (CNPq) and the Coordination for the Improvement of Higher Education Personnel (CAPES) also supported our studies.

DISCLOSURE

The authors report no conflicts of interest.

REFERENCES

[1] Helmich RC, Bloem BR (2020) The Impact of the COVID-19 Pandemic on Parkinson’s Disease: Hidden Sorrows and Emerging Opportunities. J Parkinsons Di 10, 351-354.

[2] Conde G, Quintana Pajaro LD, Quintero Marzola ID, Villegas YR, Moscote Salazar LR (2020) Neurotropism of SARS-CoV 2: Mechanisms and manifestations. J Neurol Sci, 116824.

[3] Li YC, Bai WZ, Hashikawa T (2020) The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol [Epub ahead of print].

[4] Cain MD, Salimi H, Diamond MS, Klein RS (2019) Mechanisms of Pathogen Invasion into the Central Nervous System. Neuron 103, 771-783.

[5] Dubé M, Le Coupenc A, Wong AHM, Rini JM, Desorges M, Talbot PJ (2018) Axonal Transport Enables Neuron-to-Neuron Propagation of Human Coronavirus OC43. J Virol 16, pii: e00404-18.

[6] Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, Chang J, Hong C, Zhou Y, Wang D, Miao X, Li Y, Hu B (2020) Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol [Epub ahead of print].

[7] Yan CH, Faraji F, Prajapati DP, Boone CE, DeConde AS (2020) Association of chemosensory dysfunction and Covid-19 in patients presenting with influenza-like symptoms. Int Forum Allergy Rhinol [Epub ahead of print].

[8] Spinato G, Fabbris C, Polesel J, Cazzador D, Borsetto D, Hopkins C, Boscolo-Rizzo P (2020) Alterations in Smell or Taste in Mildly Symptomatic Outpatients With SARS-CoV-2 Infection. JAMA [Epub ahead of print].

[9] Beltrán-Corbellini Á, Chico-García JL, Martínez-Poles J, Rodríguez-Jorge F, Natera-Villalba E, Gómez-Coral J, Gómez-López A, Monreal E, Parra-Díaz P, Cortés-Cuevas JL, Galán JC, Fragaola-Arnaú C, Porta-Etessam J, Masjuan J, Alonso-Cánovas A (2020) Acute-onset smell and taste disorders in the context of Covid-19: a pilot multicenter PCR-based case-control study. Eur J Neurol [Epub ahead of print].

[10] Netland J, Meyerholz DK, Moore S, Cassell M, Perlman S (2008) Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. J Virol 82, 7264-75.

[11] Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395, 507-513.

[12] Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z (2020) Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA [Epub ahead of print].

[13] Olival KJ, Daszak P (2005) The ecology of emerging neurotropic viruses. J Neurovirol 11, 441-6.

[14] Sahin AR, Erdogan A, Ağaoglu PM, Dineri Y, Çakirci AY, Senel ME, Okyay RA, Tasdogan AM (2020) 2019 Novel Coronavirus (COVID-19) Outbreak: A Review of the Current Literature. EJMO 4, 1-7.

[15] Moriguchi T, Harii N, Goto J, Harada D, Sugawara H, Takamino J, Ueno M, Sakata H, Kondo K, Myose N, Nakao A, Takeda M, Haro H, Inoue O, Suzuki-Inoue K, Kubokawa K, Oghira S, Sasaki T, Kinouchi H, Kojin H, Ito M, Onishi H, Shimizu T, Sasaki Y, Ishihara H, Furuya S, Yamamoto T, Shimada S (2020) A first Case of Meningitis/Encephalitis associated with SARS-Coronavirus-2. J Neurovirol 16, 351-354.

[16] Helms J, Kremer S, Merdji H, Clere-Jehl R, Schenck M, Kummerlen C, Collange O, Boulay C, Fat-Cremer S, Ohana M, Anheim M, Meziani F (2020) Neurologic Features in Severe SARS-CoV-2 Infection. N Engl J Med [Epub ahead of print].

[17] Sharifirazavi A, Karimi N, Rouhani N (2020) COVID-19 and intracerebral haemorrhage: causative or coincidental? New Microbes and New Infections [Epub ahead of print].
[18] Zhao H, Shen D, Zhou H, Liu J, Chen S (2020) Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? *Lancet Neurol* **19**, 383-384.

[19] Felice FG, Tovar-Moll F, Moll J, Munoz DP, Ferreir ST (2020) Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and the Central Nervous System. *Trends Neurosci* [Epub ahead of print].

[20] Limphaibool N, Iwanowski P, Holstad MJV, Kobyłarek D, Kozubski W (2019) Infectious Etiologies of Parkinsonism: Pathomechanisms and Clinical Implications. *Front Neurol* **10**, 652.

[21] Rietdijk CD, Perez-Pardo P, Garssen J, van Wezel RJ, Kraneveld AD (2017) Exploring Braak’s Hypothesis of Parkinson’s Disease. *Front Neurol* **8**, 37.

[22] Jang H, Boltz D, Sturm-Ramirez K, Shepherd KR, Jiao Y, Webster R, Smeyne RJ (2009) Highly pathogenic H5N1 influenza virus can enter the central nervous system and induce neuroinflammation and neurodegeneration. *Proc Natl Acad Sci USA* **106**, 14063-8.

[23] Sadasivan S, Zanin M, O’Brien K, Schultz-Cherry S, Smeyne RJ (2015) Induction of microglia activation after infection with the non-neurotropic A/CA/04/2009 H1N1 influenza virus. *PLoS One* **10**, e0124047.

[24] Sadasivan S, Sharp B, Schultz-Cherry S, Smeyne RJ (2017) Synergistic effects of influenza and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) can be eliminated by the use of influenza therapeutics: experimental evidence for the multi-hit hypothesis. *npj Parkinson’s Disease* **3**, 18.

[25] Karpenko MN, Muruzheva ZM, Pestereva NS, Ekimova IV (2019) An Infection Hypothesis of Parkinson’s Disease. *Neurosci Behav Physiol* **49**, 555–561.

[26] Dourmashkin RR (1997) What caused the 1918-30 epidemic of encephalitis lethargica? *J R Soc Med* **90**, 515–520.

[27] Jang H, Boltz DA, Webster RG, Smeyne RJ (2009) Viral parkinsonism. *Biochim Biophys Acta* **1792**, 714-21.

[28] Johnson ME, Stecher B, Labrie V, Brundin L, Brundin P (2019) Triggers, Facilitators, and Aggravators: Redefining Parkinson’s Disease Pathogenesis. *Trends Neurosci* **42**, 4-13.

[29] Dorsey ER, Bloem BR (2018) The Parkinson pandemic — a call to action. *JAMA Neurol* **75**, 9–10.

[30] Hou Y, Dan X, Babbar M, Wei Y, Hasselbalch SG, Croteau DL, Bohr VA (2019) Ageing as a risk factor for neurodegenerative disease. *Nat Rev Neurol* **15**, 565-581.

[31] GBD 2013 DALYs and HALE Collaborators (2015) Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. *Lancet* **28**, 2145-91.

[32] Okun MS (2013) Parkinson’s Treatment: 10 Secrets to a Happier Life. North Charelston, SC: CreateSpace Publishing.

[33] Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ; HLH Across Speciality Collaboration, UK (2020) COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet* **395**, 1033-1034.

[34] Desforges M, Le Coupanec A, Dubeau P, Bourguin A, Lajoie L, Dubé M, Talbot PJ (2019) Human Coronavirus and Other Respiratory Viruses: Underestimated Opportunistic Pathogens of the Central Nervous System? *Viruses* **12**, pii: E14.

[35] Fazzini E, Fleming J, Fahn S (1992) Cerebrospinal fluid antibodies to coronaviruses in patients with Parkinson’s disease. *Mov Disord* **7**, 153-8.

[36] Martyn CN, Osmond C (1995) Parkinson’s disease and the environment in early life. *J Neurol Sci.* **132**, 201–6.

[37] Martyn CN (1997) Infection in childhood and neurological diseases in adult life. *Br Med Bull* **53**, 24–39.

[38] Papa SM, Brundin P, Fung VSC, Kang UJ, Burn DJ, Colosimo C, Chiang HL, Alcalay RN, Trenkwalder C, MDS-Scientific Issues Committee (2020) Impact of the COVID-19 Pandemic on Parkinson’s Disease and Movement Disorders. *Mov Disord* [Epub ahead of print].

[39] Lippi A, Domingues R, Setz C, Outeiro TF, Krisko A (2020) SARS-CoV-2: At the Crossroad Between Aging and Neurodegeneration. *Mov Disord* [Epub ahead of print].

[40] Troyer EA, Kohn JN, Hong S (2020) Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms. *Brain Behav Immun* [Epub ahead of print].